Weight-Loss Drugs and ‘Eye Stroke’: Understanding the Potential Risk
Recent medical reports have raised concerns about a rare eye condition, informally termed “eye stroke,” among some users of weight-loss medications, particularly those containing semaglutide. While the risk remains small, understanding the potential connection is crucial for both patients and healthcare providers.
What is an ‘Eye Stroke’?
The term “eye stroke” refers to non-arteritic anterior ischemic optic neuropathy (NAION), a condition resulting from decreased blood flow to the optic nerve. This disruption can lead to damage of the optic nerve and subsequent vision loss, which may be partial or complete ScienceAlert. Unlike a traditional stroke, NAION often presents without other typical stroke symptoms like paralysis or speech difficulties, making early detection challenging ScienceAlert.
The Link to Semaglutide and GLP-1 Agonists
A large study analyzing over 30 million reports submitted to the U.S. Food and Drug Administration (FDA) identified approximately 31,000 cases associated with semaglutide apply Healthline. Semaglutide is the active ingredient in several popular medications, including Ozempic, Wegovy, and Mounjaro, collectively known as GLP-1 agonists. These drugs mimic the hormone GLP-1, which helps regulate appetite and blood sugar ScienceAlert.
The study indicated that Wegovy, the higher-dose formulation used for weight loss, was more closely linked to NAION than other drugs like Ozempic Healthline. Researchers hypothesize that this increased risk may be related to the drugs’ effects on blood pressure or rapid weight changes, potentially impacting blood flow in the small vessels of the eye Healthline.
Who is Most at Risk?
The research revealed a notable disparity in risk based on gender. Men were found to be three times more likely to develop NAION while taking semaglutide compared to women, although the underlying reason for this difference remains unclear Healthline. Individuals with pre-existing diabetes are also known to be at an increased risk of developing NAION ScienceAlert.
What Do the Experts Say?
Medical authorities emphasize that NAION remains a rare condition, and medications containing semaglutide offer significant health benefits, particularly in managing type 2 diabetes, reducing the risk of heart disease, and aiding weight loss Healthline. Further clinical studies are needed to fully understand the relationship between these medications and NAION, and to identify those most at risk.
What Should You Do?
If you are taking a medication containing semaglutide and experience sudden vision changes, such as blurred vision or vision loss, it is crucial to seek immediate medical attention. Early diagnosis is key to minimizing potential complications Healthline.
Looking Ahead
The increasing use of weight-loss medications worldwide, especially among younger populations, necessitates continued research and monitoring to fully assess the long-term safety profile of these drugs. Staying informed and maintaining open communication with your healthcare provider are essential steps in managing your health effectively.